Remnant pancreatic volume as an indicator of poor prognosis in pancreatic cancer patients after resection

Pancreatology. 2019 Jul;19(5):716-721. doi: 10.1016/j.pan.2019.05.464. Epub 2019 Jun 2.

Abstract

Background: Remnant pancreatic volume (RPV) is a well-known marker for short-term outcomes in pancreatic cancer patients after resection. However, in terms of the long-term outcomes, the significance of the RPV value remains unclear. Here, we address whether the RPV value is a predictor of the long-term outcomes in pancreatic cancer patients after resection by comparing various cancer-, patient-, and surgery-related prognostic factors and systemic inflammatory response markers in a retrospective cohort.

Methods: The RPV was measured on a three-dimensional (3D) image, revealing the actual pancreatic parenchymal remnant volume. Ninety-one patients who underwent pancreaticoduodenectomy were retrospectively enrolled. We divided the cohort into high- and low-RPV groups based on a cut-off value (>31.5 cm3, n = 66 and ≤31.5 cm3, n = 25, respectively). The median survival times (MSTs) were compared between the two groups. Using multivariate analysis, the RPV and other well-known prognostic factors were independently assessed.

Results: The MSTs (days) were significantly different between the two groups (high, 823 vs. low, 482, p = 0.001). Multivariate analysis identified the RPV (≤31.5 cm3) (hazard ratio [HR], 2.015; p = 0.011), lymph node metastasis (HR, 8.415; p = 0.002), lack of adjuvant chemotherapy (HR, 5.352; p < 0.001), stage III/IV disease (HR, 2.352; p = 0.029), and pathological fibrosis (HR, 1.771; p = 0.031) as independent prognostic factors.

Conclusions: The present study suggests that the RPV value is also useful for predicting long-term outcomes in pancreatic cancer patients after resection.

Keywords: 3D simulation; Pancreatic cancer; Pancreatic surgery; Pancreatic volume; Prognostic factor.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Chemoradiotherapy, Adjuvant
  • Cohort Studies
  • Female
  • Fibrosis / pathology
  • Humans
  • Lymphatic Metastasis
  • Male
  • Middle Aged
  • Neoplasm, Residual
  • Pancreas / pathology*
  • Pancreatic Neoplasms / pathology*
  • Pancreatic Neoplasms / surgery*
  • Pancreaticoduodenectomy
  • Predictive Value of Tests
  • Prognosis
  • Retrospective Studies
  • Survival Analysis
  • Systemic Inflammatory Response Syndrome / pathology
  • Treatment Outcome